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Abstract 
Background: The human epidermal growth factor receptor (HER) family of transmembrane tyrosine kinases is 
overexpressed and correlates with poor prognosis and decreased survival in many cancers. The receptor family has 
been therapeutically targeted, yet tyrosine kinase inhibitors (TKIs) do not inhibit kinase-independent functions and 
antibody-based targeting does not affect internalized receptors. We have previously demonstrated that a peptide 
mimicking the internal juxtamembrane domain of HER1 (EGFR; EJ1) promotes the formation of non-functional HER 
dimers that inhibit kinase-dependent and kinase-independent functions of HER1 (ERBB1/EGFR), HER2 (ERBB2) and 
HER3 (ERBB3). Despite inducing rapid HER-dependent cell death in vitro, EJ1 peptides are rapidly cleared in vivo, limit-
ing their efficacy.
Method: To stabilize EJ1 activity, hydrocarbon staples (SAH) were added to the active peptide (SAH-EJ1), resulting in 
a 7.2-fold increase in efficacy and decreased in vivo clearance. Viability assays were performed across HER1 and HER2 
expressing cell lines, therapeutic-resistant breast cancer cells, clinically relevant HER1-mutated lung cancer cells, and 
patient-derived glioblastoma cells, in all cases demonstrating improved efficacy over standard of care pan-HER thera-
peutics. Tumor burden studies were also performed in lung, glioblastoma, and inflammatory breast cancer mouse 
models, evaluating tumor growth and overall survival.
Results: When injected into mouse models of basal-like and inflammatory breast cancers, EGFRvIII-driven glioblas-
toma, and lung adenocarcinoma with Erlotinib resistance, tumor growth is inhibited and overall survival is extended. 
Studies evaluating the toxicity of SAH-EJ1 also demonstrate a broad therapeutic window.
Conclusions: Taken together, these data indicate that SAH-EJ1 may be an effective therapeutic for HER-driven can-
cers with the potential to eliminate triple negative inflammatory breast cancer.
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Background
The human epidermal growth factor receptor (HER) 
family consists of four transmembrane proteins (Epi-
dermal Growth Factor Receptor/HER1/ERBB1, HER2/
ERBB2, HER3/ERBB3, and HER4/ERBB4), capable of 
homo- and hetero-dimerizing and driving a variety of 
cellular activity, including migration, differentiation, 
proliferation, and cell survival [1–3]. HER1-3 misregula-
tion and mislocalization are frequently associated with 
cancers including breast, lung, and brain [4, 5]. Given 
the strong inverse correlation between HER expression 
and progression-free patient survival, current therapies 
have focused on targeting either the extracellular ligand-
binding domains through monoclonal antibodies or the 
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(TKIs) [6–8]. However, these treatments often lead to 
therapeutic resistance driven by mutations in the kinase 
domain, such as EGFR T790M, which confers Erlotinib 
(Tarceva) and Gefitinib (Iressa) resistance in lung cancers 
[9, 10]. Monoclonal antibody options are also limited, as 
they function primarily to slow cell proliferation, allow-
ing tumor re-growth upon removal; they also require the 
receptors to be at the cell surface, an event dysregulated 
in cancer [11–14]. Taken together, these data highlight 
the current limitations in targeting the extracellular or 
intracellular domains of HER proteins as viable long-
term treatment options for cancer patients.
Despite variations in extracellular ligand binding abili-
ties and intracellular tyrosine kinase activity, HER1-3 
share homology in their juxtamembrane domain [15]. 
Within the juxtamembrane domain are sequences 
responsible for targeting HER proteins to the nucleus, 
binding to calcium/calmodulin, trafficking to the baso-
lateral domain from the trans-Golgi network, and 
dimerization, an event required for HER activation and 
downstream signaling [3, 16–18]. We have previously 
demonstrated the efficacy of a therapeutic directed 
against the juxtamembrane domain region 643–663 of 
HER1 (EGFR Juxtamembrane Peptide 1—EJ1), capable 
of inhibiting HER1-3 activation, reducing calcium/calm-
odulin-associated proliferation, promoting cell death 
through necrosis and apoptosis, and reducing tumor 
growth and metastasis in MMTV-pyMT mice with mam-
mary tumors [19]. However, EJ1 was degraded in less 
than 5 min when introduced to plasma, limiting its ability 
as a therapeutic. To increase the efficacy of the peptide, 
our current research explored the use of hydrocarbon 
staples to generate a stable alpha helix (SAH) of EJ1.
Native peptides are prone to losing their conforma-
tion without the support of the full-length protein to 
stabilize the fragment, thereby limiting their potential 
binding affinity and increasing the rate of proteolytic 
degradation [20, 21]. By introducing a stabilizing modi-
fication such as the hydrocarbon bridging of amino acid 
side-chains (‘staples’), the peptide can be locked into 
a single conformation, both chemically and structur-
ally, leading to an increase in peptide half-life and bio-
availability [22]. Stapling has been effectively utilized on 
multiple peptides, including a peptide designed to block 
the degradation of p53 and an MCL-1 inhibitor, both of 
which successfully induce cancer apoptosis [21, 23–25]. 
These peptides are not only efficacious in  vitro, but a 
number have made it into clinical trials and patients. As 
of 2016, the p53-directed stapled peptide ALRN-6924 
(Aileron) has progressed to Phase II clinical trials for 
treatment of lymphoma (NCT02264613) due to its high 
tolerability in patients and strong antitumor activity 
[26, 27]. Other cyclic peptides under clinical evaluation 
include POL6326 in metastatic breast cancer (Phase 
I completed 2018; NCT01837095) and APL-2 in age-
related macular degeneration (Phase II currently recruit-
ing; NCT03453619) [27]. Three glucagon-like peptide-1 
receptor peptides have also been approved (Exenatide/
Byetta [Bristol-Myers Squibb], Liraglutide/Victoza [Novo 
Nordisk], and Lixisenatide/Lyxumia [Sanofi]) as of 2013, 
with more under regulatory review and in Phase III trials 
[28]. We therefore investigated the hypothesis that modi-
fication of EJ1 with peptide stapling would provide the 
stability required for a functional therapeutic.
Here, we demonstrate the introduction of 2α,α-
disubstituted residues subject to olefin metathesis fol-
lowed by macrocyclic bridge formation can significantly 
increase EJ1 efficacy. Visualization of Cy5.5-labeled 
peptide demonstrated whole body delivery, with a toxic 
index well below the efficacious dose. When added to 
cancer cells with or without therapeutic resistance, we 
observed significant reductions in cell viability over cur-
rent cancer therapies. Importantly, treatment of mouse 
models of breast, particularly inflammatory breast, lung, 
and glioblastoma resulted in decreased tumor burden 
and prolonged overall survival, emphasizing the thera-
peutic potential of a stapled EJ1 peptide.
Materials and methods
Peptides
The peptides were synthesized as previously described 
[19]. The hydrocarbon staple-bearing amino acids 
(R-2-{[(9H-fluoren-9-yl)methoxy]carbonylamino}-
2-methyldec-9-enoic acid and S-2-{[(9H-fluoren-9-yl)
methoxy]carbonylamino}-2-methyl-hept-6-enoic acid) 
were added during synthesis at the positions indicated in 
Fig.  1. GenScript (Piscataway, NJ) performed the initial 
small batch synthesis of stapled peptides 1–5. The yield 
for numbers 2 and 3 was insufficient for testing. Large 
scale synthesis was carried out by PolyPeptide (Torrance, 
CA), and this was used for all in vivo testing. Information 
regarding purity and identity can be found in Table  S1, 
Additional file 1.
Cell lines
MDA-MB-468 triple negative breast cancer (HER1+, 
HER2−, HER3+, HER4−) [19, 29], BT474 breast can-
cer (HER1+, HER2+, HER3+, HER4+) [30, 31], 
BT474 clone 5 (Trastuzumab-resistant) breast cancer 
(HER1+, HER2+, HER3+, HER4+) [32], A549 lung 
cancer (HER1+, HER2+, HER3+, HER4−) [33–36], 
and NCI-H1975 T790M mutant lung cancer (HER1+, 
HER2+, HER3−, HER4−) [37, 38] cells were obtained 
from ATCC and cultured in RPMI-1640 medium (Corn-
ing; Corning, NY), 5% FBS (Peak; Denver, CO), and 1% 
Pen/Strep (Corning). BT20 triple negative breast cancer 
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cells (HER1+, HER2−, HER3−, HER4−) [29, 30] were 
obtained from ATCC and cultured in Dulbecco’s modified 
Eagle’s medium (Corning), 10% FBS (Peak), and 1% Pen/
Strep (Corning). CHO cells (HER1−, HER2+, HER3−, 
HER4−) [39, 40] were obtained from ATCC and cul-
tured in F12 medium (Corning) with 10% FBS (Peak) and 
1% Pen/Strep (Corning). MCF10A breast cells (HER1+, 
HER2+, HER3+, HER4−) [41, 42] were obtained from 
ATCC and cultured in DMEM/F12 medium (Thermo 
Fisher; Waltham, MA), 5% Donor Horse Serum (Omega 
Scientific; Tarzana, CA), 1% Pen/Strep (Corning), EGF 
(Corning), Hydrocortisone (Sigma; St Louis, MO), Chol-
era Toxin (Sigma), and Bovine Insulin (Fisher). SUM149 
inflammatory breast cancer cells (HER1−, HER2−, 
HER3−, HER4−) [43] were obtained from Asterand and 
maintained in Ham’s medium (Gibco; Waltham, MA), 5% 
FBS (Peak), Insulin (Fisher), and Hydrocortisone (Sigma).
Therapeutics
Cetuximab was purchased from Thermo Fisher (MA5-
12880) and Millipore (MABF120) (Billerica, MA). Sapi-
tinib was purchased from Selleck Chem (AZD8931) 
(Houston, TX). Trastuzumab was purchased from Abso-
lute Antibody (Ab00103-10.0) (Oxford, UK).
Fig. 1 Hydrocarbon stapling leads to increased EJ1 activity in comparison to HER-directed monoclonal therapies. a EJ1 sequence with PTD4 
domain (underlined) corresponding to EGFR juxtamembrane domain sequence 643–663. Stabilized alpha helix (SAH) variations 1–5 beneath, 
with asterisks (*) indicating sites of staple. Control peptide (CP) with altered residues indicated by double underline. Stapled control (5) asterisks (*) 
indicate sites of staple. b Cartoon representation of EJ1 structure, with staple variation 5 highlighted. Positively charged residues indicated in blue, 
negatively charged residues in red [94]. c Cartoon representation of CP structure, with staple variation highlighted. d Cell viability assay performed 
in MDA-MB-468 cells after 24 h comparing unstapled EJ1 versus staple variations SAH1, SAH4, and SAH5, with increasing concentrations. e 
Visualization of MDA-MB-468 cells untreated, treated with 10 µM EJ1, and 10 µM SAH5-EJ1 after 60 min. Scale bars represent 50 µm. f–h Cell viability 
assay performed in MDA-MB-468, MCF10A, or CHO cells over 3 days comparing treatment with Sapitinib (blue lines), SAH5-EJ1 (red lines), and 
SAH5-CP (grey lines). Solid lines represent 24 h; dashed lines represent 72 h. i Cell viability assay performed in BT474 cells over 3 days comparing 
treatment with Trastuzumab (µg/mL) (blue) to SAH5-EJ1 or SAH5-CP (µM) (red and grey, respectively). p < 0.001 in all cases unless indicated by NS 
for p > 0.05. Data shown in d, f, g–i represent mean ± percent difference of assays performed in triplicate
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Fluorophore
Cyanine5.5 NHS ester (27020; Lumiprobe; Hunt Val-
ley, MA) was conjugated to the peptide according to the 
manufacturers protocol. Unconjugated and precipitated 
dye was removed by centrifugation.
Cell viability assay
1000–3000 cells were plated in 96-well plates (Falcon; 
Corning, NY) and allowed to adhere for 24–48 h prior to 
therapeutic introduction. Compounds were added and 
incubated on cells for 3 days in serum-containing media, 
followed by 2 h treatment with MTT (Sigma M5655) with 
the resulting formazan solubilized in DMSO. Absorbance 
was read at 540  nm by plate reader (uQuant, Bio-Tek 
Instruments). P-values were calculated from a one-way 
ANOVA.
Live imaging
BT20 cells were treated with 150  nM MitoTracker Red 
CMXRos (Molecular Probes; Carlsbad, CA) for 90  min 
at 37  °C in serum-containing media. MitoTracker-con-
taining media was removed, cells were treated with 
5  µM Cy5.5-SAH5-EJ1 and imaged every 5  min for up 
to 60 min using the Leica SP5-II confocal microscope at 
63× at 37 °C.
Imaging
Immunofluorescence images were taken using a Leica 
DMLB microscope and Leica DFC 310 FX camera 
mounted on a 1× C-mount using the LAS V4.5 software. 
Whole Mouse imaging was performed by the Arizona 
Cancer Imaging Shared Resource and used LagoX (Spec-
tral Instruments Imaging) software-AMI View (v1.7.05).
Western blots and lysates
Tumor lysates were generated by injecting SUM149 
cells into the mammary fat pads of NOD/SCID mice in 
Matrigel, allowing tumors to grow to 200 cubic mm and 
then mice were placed into arms. At the points indi-
cated for each study, mice were dosed with the indicated 
quantities of SAH5-EJ1 or diluent (control arms) and 
monitored. Mice were sacrificed and tumor lysates were 
produced immediately. Cell lysates were generated as 
previously described [19]. Antibodies were purchased 
from Cell Signaling (Danvers, MA)—pCaMKII (D21E4), 
AKT (9272), IKKα (11930), pEGFR Y845 (2231), HER2 
(2242L), Santa Cruz Antibodies (Dallas, TX)—EGFR 
1005, and Sigma-Aldrich—dpERK (1/2) (M7802), β-actin 
(A5441). Western blotting was performed as previously 
described [19].
Mouse model; inflammatory breast cancer
26 female SCID mice were injected with 0.1 mL of a cell 
solution containing 3.84 × 106 SUM149 cells resuspended 
in Trevigen and sterile saline at site L4. Mice were incu-
bated for 35 days to allow tumor growth prior to injection 
of SAH5-EJ1, and randomized into 3 groups, N = 8 mice/
group. Injections of 5  µg/g or 0.5  µg/g in 0.1  mL vol-
umes of SAH5-EJ1 were administered via tail vein every 
3 days for 31 days until the administration route changed 
to intraperitoneal injections through the conclusion of 
the study. Control injections of equal volumes of sterile 
water were also performed. All animals were maintained 
as outlined by University of Arizona Institutional Animal 
Care and Use Committee (IACUC) by the Experimental 
Mouse Shared Resource (EMSR).
Toxicity study
Toxicology was performed by IITRI. The study was 
conducted in compliance with the US Food and Drug 
Administration (FDA) good laboratory practice (GLP) 
Regulations (Code of Federal Regulations Title 21 Part 58) 
to evaluate the toxicokinetics, local tolerability, immu-
nogenicity, and potential toxicity of SAH5-EJ1 following 
three times per week intravenous (IV) dosing for 28 days 
in mice. Male and female CD-1 IGS [Crl:CD1(ICR)] mice 
(135 per sex) were received from Wilmington, MA-based 
Charles River Laboratories, Inc.’s Kingston facility (Stone 
Ridge, NY).
Patient‑derived xenografts; breast and lung
The following PDX mouse models were generated by 
Jackson Labs (Sacramento, CA): Breast TM01278; Grade 
3 invasive ductal carcinoma, primary malignancy; EGFR 
inactivating R521K mutation; ERBB3 G1288A muta-
tion in kinase domain with unknown effects on activity; 
increased EGFR/ERBB2/ERBB3. Lung TM00784; Grade 
3 lung adenocarcinoma, primary malignancy; EGFR 
activating L858R mutation; increased EGFR, decreased 
ERBB2/ERBB3/ERBB4. All animals were maintained as 
outlined by University of Arizona Institutional Animal 
Care and Use Committee (IACUC) by the Experimental 
Mouse Shared Resource (EMSR).
Patient‑derived xenografts; glioblastoma
Patient samples used were provided by the Biobank 
Core Facility at Barrow Neurological Institute. Samples 
were de-identified and conformed to the Biobank IRB 
protocol. Patient-derived cell lines (GB16 and GB71) 
were established from resected primary GBM tumor 
tissue. Tissue was processed using the Gentle MACS 
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Dissociator and Tumor Tissue Dissociation kit (Miltenyi 
Biotec Inc.; Auburn, CA). Animal husbandry was per-
formed according to the guidelines of St. Joseph Hospital 
and Medical Center and Barrow Neurological Institute 
under the Institutional Animal Care and Use Committee-
approved protocol. Five- to six-week-old CrTac: NCr-
Foxn1nu nude mice (Taconic Biosciences; Hudson, NY) 
were used for in vivo orthotropic transplant of luciferized 
murine glioma model [44] (Ink4a/ARF−/−; hEGFRvIII). 
For orthotopic transplants, 2  μL of dissociated cells at 
a density of 100,000 cells/μL were injected in the right 
striatum, as described previously [44, 45]. In vivo tumor 
growth was measured by IVIS xenogen biolumines-
cence imaging (BLI) system after IP injection of 150 mg/
kg Luciferin (Gold Biotechnology; St, Louis, MO) every 
week after 1-month post-surgery. Tumor-bearing animals 
were euthanized at the onset of neurological symptoms.
Glioblastoma cell viability assay
Cells were expanded as neurospheres in tissue culture 
dishes coated with poly-(2-hydroxyethyl methacrylate) 
(Sigma-Aldrich) or grown adherent on laminin (Fisher), 
in DMEM and F12-Glutamax supplemented with B27 
and N2 (Fisher), in the presence of 20  ng/mL EGF and 
20  ng/mL FGF2 (Millipore). For dose response curves, 
10,000 cells/well were plated on a laminin-coated 96-well 
plates. Cells were treated the following day with indicated 
doses of either the control peptide or SAH5-EJ1. The cell 
viability was assessed 48 h post-treatment with Cell Titer 
Glo (Promega; Madison, WI) and a Tecan plate reader.
Results
Hydrocarbon stapling of EJ1 increases intracellular activity
We have previously demonstrated treatment of breast 
tumors in  vivo with a peptide directed against the jux-
tamembrane domain of the HER protein family (EJ1) 
reduced tumor growth and metastasis but was rapidly 
cleared in  vivo [19]. To enhance peptide stability, we 
introduced multiple variations of hydrocarbon stapling 
(Fig.  1a; Table  S1, Additional file  1), a chemical process 
which locks alpha-helices in a single native conforma-
tion [20]. Staples were oriented opposite the active face 
of the helix containing positively charged arginine resi-
dues, as well as away from sequences overlapping the 
nuclear localization sequence, the calmodulin binding 
domain, the dimerization domain, and the basolateral 
targeting sequence (Fig.  1b). Of the 5 attempted con-
formations, SAH2-EJ1 and SAH3-EJ1 were incapable 
of being synthesized. Comparison of unstapled EJ1 to 
SAH-EJ1 treatment on cell viability in MDA-MB-468 
breast cancer cells showed that all three staple confor-
mations enhanced the efficacy of EJ1 (IC50 = 18  µM; 
SAH1-EJ1 [IC50 = 10  µM]; SAH4-EJ1 [IC50 = 10  µM]; 
and SAH5-EJ1 [IC50 = 2.5  µM]). The most significant 
decrease in cell survival was observed with SAH5-EJ1 
treatment (more than 7-fold; Fig. 1d). We had previously 
observed EJ1 induced membrane blebbing and the crea-
tion of vacuolar compartments during cell death as a part 
of necrosis (evaluated by the nuclear release of HMGB1), 
and we found a similar phenotype upon treatment with 
SAH5-EJ1 (Fig. 1e) [19].
We additionally created a stapled control peptide (SAH5-
CP) in which the basic residues of the peptide face were 
replaced with acidic residues, and the peptide was simi-
larly stapled (Fig. 1a, c). We had previously shown that sin-
gle amino acid substitutions in each of the tripartite basic 
regions of EJ1 could alleviate function [19]. Here we dem-
onstrate that modifying a similar peptide with hydrocar-
bon stapling enhanced the function of this control as well. 
While the control still has significantly impaired function 
compared to the parental peptide, it did retain some activ-
ity (Fig. 1f). In MDA-MB-468 breast cancer cells, complete 
cell death is achieved with 4  µM treatment of SAH5-EJ1 
after 1  day, while the same concentration of the control 
peptide results in only 25% cell death. Doubling the con-
centration of this peptide results in 70% cell death (Fig. 1f).
To determine if this effect was due to the dependence 
of MDA-MB-468 cells on HER1 (HER1 is amplified in 
this cell line) [46, 47], we tested two additional cell lines; 
MCF10A, an immortalized breast mammoplasty cell line 
that expresses HER1 but not HER2 [48–50] and Chinese 
Hamster Ovary (CHO) cells, which express HER2 but 
not HER1 [51]. Relative levels of HER expression has 
been previously published in Hart et al. and can also be 
found in Figure S1, Additional file  1 [19]. Additionally, 
we compared SAH5-EJ1 and the stapled control peptide 
(SAH5-CP) to the pan-HER kinase inhibitor Sapitinib 
(AZD8931), selected due to its simultaneous targeting 
of HER1, HER2, and HER3 [52]. In MCF10A breast cells 
with non-amplified HER1, we found that while the cells 
responded to Sapitinib (demonstrating at most a 70% 
reduction after 72  h of treatment—dashed blue lines), 
complete cell death was not observed with SAH5-EJ1 
until a concentration of 10  µM (Fig.  1g). Additionally, 
the control peptide had no significant effect on MCF10A 
cells at any concentration tested. Next, we compared 
SAH5-EJ1 and Sapitinib in HER1 negative and HER2 
positive CHO cells [19]. We found that Sapitinib has lim-
ited efficacy, but SAH5-EJ1 induces significant cell death 
between 5 and 10 µM (Fig. 1h—red lines).
Given the efficacy of SAH5-EJ1 against HER2-expressing 
cell lines (13% cell viability versus 67% at 5 µM—Fig. 1g, h 
respectively), we next tested SAH5-EJ1 versus the mono-
clonal antibody therapy Trastuzumab (Herceptin) (anti-
HER2 antibody), also monitoring responses in cells with 
therapeutic resistance to Trastuzumab. Importantly, the 
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Trastuzumab-resistant cell lines are still capable of binding 
the antibody to cell surface receptors and do not present 
with reduced levels of HER2 expression; rather, the resist-
ance is driven through loss of cyclin-dependent kinase 
inhibitor p27 expression in the nucleus [32]. Using the 
HER2-amplified BT474 breast cancer cell line, both Tras-
tuzumab-sensitive (Parental) and Trastuzumab-resistant 
(Resistant) cells were treated with increasing doses of Tras-
tuzumab, SAH5-EJ1, or SAH5-CP, beginning with 2.5 µg/
mL (Trastuzumab) or 2.5  µM (peptides), respectively. 
Parental cell survival decreased to approximately 25% after 
3 days of treatment with Trastuzumab (Fig. 1i, solid blue 
bars); as expected, Trastuzumab-resistant cells maintained 
almost 50% cell survival (Fig. 1i, cross-hatched blue bars). 
However, both parental and resistant BT474 cells demon-
strated significant responses to SAH5-EJ1, particularly at 
10 µM doses (resulting in approximately 50% and 5% cell 
survival, respectively; Fig. 1i, solid and cross-hatched red 
bars), highlighting the potential of SAH5-EJ1 as a thera-
peutic option in cancers that have become resistant to 
Trastuzumab. No response was observed in cells treated 
with SAH5-CP, regardless of Trastuzumab resistance 
(Fig. 1i), a trend also seen in CHO cells (Fig. 1h).
Evaluating the efficacy of SAH5-EJ1 to HER1 versus 
HER2 expressing cells indicate that HER1-expressing 
cells have increased sensitivity over HER2-expression 
alone. The partial response of HER1-expressing cells 
to the control peptide (MDA-MB-468 and MCF10A; 
Fig. 1f, g, respectively) versus the lack of response HER2-
expressing cells (CHO and BT474) would indicate that 
the peptide sequence is more sensitive to HER1, given the 
sequence is derived from HER1 and not HER2 (despite 
some conserved homology within the protein family).
SAH5‑EJ1 is effectively delivered intracellularly 
and throughout the body
To determine the localization and distribution of SAH5-
EJ1, the NHS ester form of the far-red Cy5.5 fluorophore 
was conjugated to the peptide (Cy5.5-SAH5-EJ1). Treat-
ment of HER1-expressing BT20 breast cancer cells 
resulted in immediate uptake of SAH5-EJ1, with peptide 
distribution throughout the cell (Fig.  2A–C). We have 
previously discussed the ability of HER1 to be targeted to 
the mitochondria via the nuclear localization sequence, 
particularly in HER-dependent cancers [19, 53–55]. We 
also reported the unstapled EJ1 peptide colocalizes with 
the mitochondria and that this is key to reactive oxygen 
species (ROS) release, a primary mechanism of death by 
EJ1 [19]. Treating BT20 cells simultaneously with Cy5.5-
SAH5-EJ1 and MitoTracker Red revealed colocaliza-
tion of SAH5-EJ1 with the mitochondria within 5  min 
(Fig. 2D, arrowheads). Over 30 min, continued exposure 
of the cells to the peptide promoted a change in mito-
chondrial shape (Fig.  2E, arrowheads), culminating in 
rupturing of the cell and the mitochondria, with cor-
responding decreases in SAH5-EJ1 and mitochondrial 
luminescence (Fig. 2F, arrowheads).
To determine distribution of SAH5-EJ1 in vivo, Cy5.5-
SAH5-EJ1 was injected into wildtype FVB mice using a 
subcutaneous (SC) or intravenous (IV) route, at 10 µg/g 
body weight dosages and visualized after 30  min and 
24 h (Fig. 2 and Figure S2, Additional file 1). Control IV 
injections with the Cy5.5 fluorophore primarily displayed 
accumulation at the injection site in the tail (Fig. 2G, left). 
SC injection of labeled SAH5-EJ1 also showed a strong 
fluorescent signal at the injection site (Fig. 2G, middle). 
Alternatively, mice which received Cy5.5-SAH5-EJ1 tail 
vein injections presented with well-distributed peptide 
throughout the body, with increased concentrations in 
the head (Fig. 2G, right). The peptide was not detectable 
in plasma levels by 4  h in male mice and 2  h in female 
mice at the highest body weight dosage, and fluorescence 
was substantially reduced after 24  h (Table  1; Figure 
S2, Additional file  1). It is possible a maximum solubil-
ity of the drug is reached at the lowest range of dosing, 
resulting in no observable change in total drug plasma 
Fig. 2 SAH5-EJ1 enters cells, colocalizes with mitochondria, and survives in vivo, resulting in glioblastoma-derived cell death and glioma mouse 
model survival. A–C BT20 cells treated with Cy5.5-dye. A’ Cy5.5-only treatment, no SAH5-EJ1. B’ 10 µM Cy5.5-SAH5-EJ1. C’ 20 µM Cy5.5-SAH5-EJ1. 
Cells were incubated with Cy5.5 ± conjugation to SAH5-EJ1 (red) and mounted in DAPI (blue). Scale bars represent 50 µm. D–F Colocalization of 
SAH5-EJ1 with mitochondria in BT20 breast cancer cells. Cells were incubated with Cy5.5-SAH5-EJ1 (green) and MitoTracker Red (red). Single prime 
(‘) images represent single channel Cy5.5-SAH5-EJ1, double prime (“) images represent single channel MitoTracker Red. Arrowheads highlight 
changes in mitochondrial appearance. Scale bars represent 10 µm. G Mice were treated with Cy5.5-dye ± conjugation to SAH5-EJ1 and imaged 
after 30 min. Left mouse was treated with Cy5.5 dye through intravenous (IV) tail-vein injection. Middle mouse received Cy5.5-conjugated SAH5-EJ1 
through subcutaneous (SC) injection in the right flank. Right mouse was treated with Cy5.5-conjugated SAH5-EJ1 through tail-vein (IV) injection. 
Experiment done in duplicate and representative images selected. Radiance scale provided on the left. H Luminescence distribution throughout 
organs. Cy5.5 dye only (left) versus Cy5.5-conjugated SAH5-EJ1 (right). B brain, H heart, Lu lung, K kidney, Li liver, S stomach. Radiance scale provided 
on left. I Cell viability assay performed in two glioblastoma-derived human cell lines (solid versus dashed) over 2 days comparing treatment with 
control peptide (CP) (grey lines) to SAH5-EJ1 (red lines). J Kaplan–Meier curve of glioblastoma mouse model treated with intravenous control 
peptide (blue) or 10 µg/g SAH5-EJ1 (red). Data shown represents mean. N = 6 for control, N = 4 for SAH5-EJ1. At the time of the GBM study, tumors 
formed when compound was limiting. Therefore, while enough compound was present for 4 mice, any extra mice were placed into the control arm
(See figure on next page.)
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concentration. To identify where Cy5.5 ± SAH5-EJ1 
accumulated in the mice, organs were collected post 24 h 
in  vivo imaging and examined for Cy5.5 fluorescence 
directly. In mice treated with only the fluorophore, fil-
tering organs such as the liver and kidneys displayed the 
highest concentrations (Fig.  2H, left). In contrast, IV-
injections of Cy5.5-SAH5-EJ1 led to peptide distribution 
in all organs evaluated, with the highest concentrations in 
the kidneys and lungs, as well as observable signal in the 
brain, liver, and stomach (Fig. 2H, right). Taken together, 
these data indicate that SAH5-EJ1, upon IV injection, is 
distributed throughout the body and can accumulate in 
the brain, potentially bypassing the blood–brain-barrier.
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SAH5‑EJ1 promotes cell death in EGFRvIII 
glioblastoma‑derived cell lines and increases survival 
in mouse models
Given the ability of SAH5-EJ1 to accumulate in the brains 
of injected mice, we wanted to evaluate its efficacy in the 
EGFRvIII mutant model of brain cancer. Glioblastoma 
multiforme is characterized as an aggressive disease 
driven by EGFR amplification and mutations, limited 
in therapies due to the challenge of crossing the blood–
brain–barrier [56–58]. To evaluate the potential efficacy 
in this model, we treated patient-derived cell lines con-
taining an EGFRvIII mutation in  vitro. We found that 
SAH5-EJ1 resulted in significantly greater cell death at 
doses as low as 5  µM (Fig.  2I, red lines), compared to 
the almost 100% survival after 48 h of treatment with a 
control peptide (Figs. 1a; 2I, grey lines). Given this strong 
efficacy in vitro, we next examined the therapeutic poten-
tial of SAH5-EJ1 in an orthotopic EGFRvIII glioblastoma 
mouse model (Figure S3, Additional file 1) and found that 
treatment with 10 µg/g body weight dosages of SAH5-EJ1 
significantly prolonged survival, with 75% of the mice still 
alive after 72 days (the only mouse death occurred after 
70  days from a non-neurological disease) (Fig.  2J, red 
line) in comparison to only 16% of mice alive in the con-
trol peptide cohort (Fig.  2J, blue line). These data dem-
onstrate that SAH5-EJ1 has strong therapeutic potential 
in EGFRvIII mutant glioblastoma and we next set out to 
evaluate its efficacy in lung and breast cancers.
Table 1 SAH5-EJ1 concentration in male and female mouse plasma
Blood collection time point day 1 taken at 0.5, 1, 2, 4, 8, and 24 h post tail-vein injection. Average values represent peptide concentration ± standard deviation. N 
represents number of mice per group. × represents time points at which blood collection was not required. BQL represents below quantifiable limits (0.5 µg/mL). 
Three mice were bled at each time point
Italic values indicate average of SAH5-EJ1 concentrations in plasma
Treatment N SAH‑EJ1 concentration (µg/mL)
0.5 h 1 h 2 h 4 h 8 h 24 h
Male
 Control 3 × BQL × × × ×
 5 mg/kg 6 1.04 0.548 BQL BQL BQL BQL
6 1.36 0.603 BQL BQL BQL BQL
6 0.658 BQL BQL BQL BQL BQL
Average 1.02 ± 0.35 0.576 ± 0.039 – – – –
 10 mg/kg 6 0.684 0.568 BQL BQL BQL BQL
6 0.514 0.589 BQL BQL BQL BQL
6 0.716 0.839 BQL BQL BQL BQL
Average 0.638 ± 0.11 0.665 ± 0.150 – – – –
 15 mg/kg 6 0.75 BQL BQL BQL BQL BQL
6 1.07 0.63 0.551 BQL BQL BQL
6 0.884 0.683 BQL BQL BQL BQL
Average 0.901 ± 0.16 0.657 ± 0.037 0.551 – – –
Female
 Control 3 × BQL × × × ×
 5 mg/kg 6 0.561 BQL BQL BQL BQL BQL
6 0.555 0.508 BQL BQL BQL BQL
6 0.59 0.55 BQL BQL BQL BQL
Average 0.569 ± 0.019 0.529 ± 0.030 – – – –
 10 mg/kg 6 0.53 0.565 BQL BQL BQL BQL
6 0.616 BQL BQL BQL BQL BQL
6 0.539 0.518 BQL BQL BQL BQL
Average 0.562 ± 0.047 0.542 ± 0.033 – – – –
 15 mg/kg 6 0.508 0.588 BQL BQL BQL BQL
6 0.599 BQL BQL BQL BQL BQL
6 BQL 0.55 BQL BQL BQL BQL
Average 0.554 ± 0.064 0.569 ± 0.027 – – – –
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SAH5‑EJ1 is effective in vitro and prolongs survival in PDX 
models of lung cancer within a therapeutic window
Approximately 10% of lung adenocarcinomas are driven 
by HER1 upregulation and kinase domain activating 
mutations, with HER1-targeted TKIs such as Sapitinib as 
standard of care [59–61]. Sapitinib is capable of target-
ing HER1-3, making it a potentially more potent inhibi-
tor of HER-driven cancers and is particularly effective 
against HER mutants [52]. We first evaluated the efficacy 
of SAH5-EJ1 compared to Sapitinib in lung adenocarci-
noma cell lines representing wildtype HER1 (A549) and 
the HER1 T790M mutation (H1975) [36, 37]. In both lines, 
cells were significantly more responsive to SAH5-EJ1 treat-
ments than Sapitinib (Fig. 3a, b). This was demonstrated at 
both 24 and 72 h, where SAH5-EJ1 reduced cell survival to 
less than 5% with a 10 µM dose in the HER1 wildtype line 
(Fig.  3a, red lines), and 100% cell death after 72  h in the 
mutated HER1 line with a 10 µM dose (Fig. 3b, comparing 
dashed red line to dashed blue line).
We next investigated the potential efficacy of SAH5-
EJ1 in the mouse model of a patient-derived lung adeno-
carcinoma in which the patient had been treated with 
the HER1 specific TKI Erlotinib and had developed 
resistance (TM00784). IV injection of either 1  µg/g or 
10 µg/g body weight dosages resulted in more than a 50% 
decrease in average tumor burden (Fig. 3c). In association 
with the slowed tumor growth rate was a corresponding 
increase in survival, with mice treated with low- or high-
dose SAH5-EJ1 living 1.7× longer than control-treated 
mice (Fig. 3d, green line and red line, respectively). There 
Fig. 3 SAH5-EJ1 inhibits growth and prolongs survival in PDX models of lung cancer. a, b Cell viability assays performed in A549 or EGFR T790M 
mutated H1975 lung adenocarcinoma cells over 3 days comparing treatment with Sapitinib (blue lines) to SAH5-EJ1 (red lines). Solid lines represent 
24 h; dashed lines represent 72 h. Data shown represent mean ± percent difference of assays performed in quadruplicate. c Reduction in tumor 
burden in Erlotinib-resistant lung cancer PDX mouse model TM00784 with various doses of intravenous SAH5-EJ1. Control represents water as a 
vehicle control. *p < 0.05 (Control vs 1 µg/g); **p < 0.01 (Control vs 1 µg/g and vs 10 µg/g). d Kaplan–Meier curve of lung PDX mouse model treated 
with control (blue line) or either 1 or 10 µg/g SAH5-EJ1 (green line and red line, respectively). Data shown represent mean. N = 6 for all groups
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was no detected toxicity observed in the model within 
the therapeutic window, again emphasizing the poten-
tial therapeutic usage of SAH5-EJ1 in HER-driven can-
cers, even in those with resistance to other HER-directed 
therapies.
SAH5‑EJ1 inhibits basal models of breast cancer
We next examined the efficacy of SAH5-EJ1 in a patient-
derived xenograft of grade 3 invasive ductal breast car-
cinoma (TM01278) with increased expression of HER1 
(with an R521K mutation that reduces ligand bind-
ing [62]) and increased expression of HER3 (carrying a 
G1288A mutation in the kinase domain [8]). SAH5-EJ1 
treatment slowed tumor growth, with a significant dif-
ference in efficacy with 1  µg/g and 10  µg/g SAH5-EJ1 
compared to the control treatment (Fig.  4a). We also 
demonstrated a 2.5-fold increase in survival when treated 
with 1 µg/g SAH5-EJ1 (Fig. 4b, green versus blue lines). 
However, all remaining mice treated with 10 µg/g SAH5-
EJ1 had to be sacrificed after 41 days on the study due to 
toxicity at the injection site, a trend seen with increas-
ing concentrations of the peptide (Fig. 4b, red asterisks; 
Table  S2, Additional file  1). Taken together with basal 
breast cancer cell data previously introduced (Fig.  1i), 
these data indicate that SAH5-EJ1 can function both 
in vitro and in vivo for targeting breast cancers, including 
those with Trastuzumab resistance.
SAH5‑EJ1 effectively targets triple negative inflammatory 
breast cancer
Inflammatory breast cancer is an aggressive form of 
breast cancer, presenting with low disease-free progres-
sion and commonly associated with amplifications and 
overexpression of the HER proteins [63–65]. Current 
standard of care includes treatment with HER TKIs, often 
in combination with surgical resection [66–68]. However, 
therapeutic resistance is common, indicating a possible 
advantage in a HER-targeted therapeutic directed at the 
juxtamembrane domain.
We evaluated the efficacy of SAH5-EJ1 versus the TKI 
Sapitinib in the inflammatory breast cancer line SUM149 
in  vitro [36]. SAH5-EJ1 was significantly more effec-
tive than Sapitinib after 24 h, decreasing cell viability to 
less than 20% with 5  µM doses (Fig.  4c, solid red line). 
In contrast, Sapitinib demonstrated no reduction in cell 
viability when treated after 24 h, even at the highest dos-
age of 10  µM (Fig.  4c, solid blue line). When incubated 
for 3 days at 10 µM doses, Sapitinib was able to reduce 
viability to 35% (Fig. 4c, dashed blue line) with SAH5-EJ1 
reducing viability to zero (Fig. 4c, dashed red line). These 
data indicate that in inflammatory breast cancer, SAH5-
EJ1 is more effective at inhibiting cell survival in vitro.
We next wanted to examine the effects of SAH5-EJ1 
in inflammatory breast cancer in  vivo. NOD-SCID mice 
were injected with SUM149 cells embedded in extracellu-
lar matrix (Trevigen) in the mammary fat pad and tumors 
were allowed to establish (approximately  200mm3). IV 
injection occurred every 3  days (starting at day 35) for 
1  month until SAH5-EJ1 administration was changed 
to intraperitoneal (IP) injections through the end of the 
study, due to reactivity at the injection site (Fig. 4e, arrow). 
Injection of SAH5-EJ1 (0.5  µg/g or 5  µg/g body weight 
dosages) resulted in a significant reduction in tumor 
burden, a trend maintained through the end of the study 
(Fig. 4e). Of note, within 55 days of treatment with SAH5-
EJ1, all animals on the study showed no residual tumor 
burden. To evaluate the effects of treatment on overall 
survival, animals continued treatments for up to 203 days. 
By the end of the study, more than 40% of the SAH5-EJ1 
treated mice remained with relatively low tumor burdens 
and were sacrificed upon the completion of the study, in 
contrast to the entire control group population which was 
sacrificed due to excessive tumor burden (over 2000 mm3) 
(Fig.  4d). Over time, resistance occurred, with 9/16 
Fig. 4 SAH5-EJ1 effectively treats models of basal and inflammatory breast cancers while increasing survival. a Changes in tumor burden in breast 
cancer PDX mouse model TM01278 with various concentrations of intravenous SAH5-EJ1. Control represents water as a vehicle control. *p < 0.05 
(Control vs 1 µg/g); **p < 0.01 (Control vs 1 µg/g and vs 10 µg/g). N = 6 for each condition. b Kaplan–Meier curve of breast PDX mouse model 
treated with control (blue) or either 1 or 10 µg/g SAH5-EJ1 (green and red, respectively) (red asterisks indicate time point at which mice could no 
longer receive injections due to site toxicity). Data shown represent mean. N = 6 for all groups. c Cell viability assay performed in SUM149 cells 
over 3 days comparing treatment with Sapitinib (blue) to SAH5-EJ1 (red) and SAH5-CP (grey). Solid lines represent 24 h; dashed lines represent 
72 h. Data shown represent mean ± percent difference of assays performed in triplicate. d Kaplan–Meier curve of inflammatory breast cancer 
SUM149-injected mouse model treated with injected control (water) (blue) or either 0.5 or 5 µg/g SAH5-EJ1 (green and red, respectively). Data 
shown represent mean. N = 8 for all groups. e Changes in tumor burden in SUM149-generated tumors with various doses of SAH5-EJ1. Control 
represents water (blue). Arrow indicates transition from intravenous (IV) SAH5-EJ1 injections to intraperitoneal (IP) on day 66. **p < 0.01 (Control 
vs 0.5 µg/g and vs 5 µg/g). Data shown represent mean ± standard deviation. N = 8 for all groups. f Images of mouse tumors taken on Day 116. 
Arrowheads indicate tumor site. Representative images selected. N = 8 for each condition. g Lysates were taken from tumors in mice injected 
with SAH5-EJ1 intravenously (IV) for 31 days of the study or mice transitioned to intraperitoneal flank (IP) injections for the remainder of the study. 
Control lanes represented by untreated SUM149 cells. Lysates separated by SDS-PAGE and molecular weights are indicated on the right
(See figure on next page.)
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treated mice displaying tumor regrowth. In addition to a 
reduction in tumor mass, we also found the inflammatory 
nature of the tumor also regressed upon treatment, and 
the wounds healed to almost complete closure (Fig.  4f, 
arrowheads). Note that both 0.5  µg/g and 5.0  µg/g body 
weight dosages were sufficient to induce near-complete 
regression, with the 0.5 µg/g cohort also presenting with 
overall longer survival (Fig. 4e). When lysates were taken 
from the tumors, we observed significant reductions in 
total EGFR, phosphorylated EGFR, MAP Kinase (dpERK), 
and IKKα, while an increase total levels of AKT was also 
observed (Fig. 4g).
Finally, we confirmed the maximum tolerated dose of 
SAH5-EJ1, evaluating 5, 10, and 15  mg/kg body weight 
dosages (Table  S3, Additional file  1). Although the injec-
tion site reactogenicity was seen following intravenous 
injection of SAH5-EJ1 at all three dose levels evaluated, 
no evidence of any systemic or target organ toxicity was 
seen at any dose level after a 28-day repeat toxicity study 
(Tables S2 and S4, Additional file  1). At 15  mg/kg, one 
male animal died from unknown causes and was classi-
fied as an accidental death. Therefore, 10 mg/kg was con-
sidered the no-observed-adverse-effect level (NOAEL). 
While the NOAEL level for SAH5-EJ1 is 10 mg/kg, tumor 
ablation is achieved at 0.5 mg/kg in triple negative inflam-
matory breast cancer, demonstrating a safe therapeutic 
window. Increased spleen weights observed in 10  mg/
kg and 15  mg/kg-treated mice most likely resulted from 
extramedullary hematopoiesis, also known as “blueberry 
muffin baby syndrome”, an asymptomatic event in which 
red blood cells accumulate outside of the bone marrow 
[69, 70] (Table S5, Additional file 1). Increased spleen size 
is likely due to an increase red blood cell production asso-
ciated with IV injection-affiliated cell death [71]. Clinical 
chemistry panels indicate that despite the high concentra-
tion of SAH5-EJ1 in the liver, liver function is not inhib-
ited, with normal ranges of ALT/AST and total bilirubin 
(Table 2) [72].
Discussion
We have previously demonstrated the efficacy of thera-
peutics directed at the juxtamembrane domain of HER 
proteins [19]. Here we set out to determine the effects of 
stabilizing a peptide through α,α-hydrocarbon staples by 
examining changes in cancer cell viability and tumor pro-
gression. We found the stapled peptide was significantly 
more efficient at killing cancer cells, even when com-
pared to current HER-directed therapeutics, both mono-
clonal antibodies and TKIs. SAH5-EJ1 also demonstrated 
increased efficacy in  vivo, resulting in reduced tumor 
growth rates and prolonged survival. Taken together, 
these data indicate the improved therapeutic potential of 
the EJ1 peptide when stapled, particularly in comparison 
to standard HER-targeted cancer therapeutics.
Current therapies are limited by their dependence to 
single receptors or specific protein sequences, which, if 
mutated, can render the therapy ineffective. Studies have 
shown that even when treating HER2-positive breast can-
cer with Trastuzumab, only 35% of patients respond, due 
to mutations in the HER2 receptor or the activation of 
other tyrosine kinase pathways [8, 73]. This problem may 
be avoided through SAH5-EJ1 juxtamembrane domain 
targeting, which demonstrated significantly greater effi-
cacy when compared to Trastuzumab treatments in vitro 
(Fig. 1i). Single-target therapies are also limited by HER-
receptor cooperation, which promote activation of mul-
tiple downstream pathways, allowing signal transduction 
to remain unattenuated even with the inhibition of one of 
the receptors [74]. We have previously shown that using 
a peptide directed at the conserved domain of HER pro-
teins promotes the formation of inactive HER dimers, 
overcoming this potential downfall [19].
Tyrosine kinase inhibitors are considered more effec-
tive than monoclonal antibodies as there remains more 
homology between HER1 and HER2 kinase domains, 
allowing for the potential targeting of multiple fam-
ily members simultaneously [75]. However, given the 
Table 2 Liver enzyme function in male and female mouse plasma after 29 days SAH5-EJ1 treatment
Blood collection for clinical chemistry analysis were collected via retro-orbital sinus puncture prior to scheduled necropsy on Day 29 and quantified using a Beckman 
Coulter AU480 Clinical System (Beckman Coulter; Brea, CA). Average values ± standard deviation. N represents number of mice per group. BUN blood urea nitrogen, 
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin
a AST significance determined via ANOVA-DUNNETT analysis
b TBIL significance determined via Kruskal–Wallis-Dunn analysis
Male Female
Control 5 mg/kg 10 mg/kg 15 mg/kg Control 5 mg/kg 10 mg/kg 15 mg/kg
BUN (mg/dL) 30 ± 9.7 26 ± 2.2 31 ± 7.3 23 ± 2.9 22 ± 5.2 19 ± 2.2 19 ± 3.0 22 ± 2.5
ALP (IU/L) 54 ± 12.9 68 ± 13.8 73 ± 19.7 58 ± 10.5 95 ± 38.8 88 ± 33.2 70 ± 48.4 62 ± 18.4
ALT (IU/L) 107 ± 29.7 124 ± 71.5 96 ± 28.3 67 ± 32.3 88 ± 22.8 79 ± 35.0 61 ± 18.5 90 ± 27.2
AST (IU/L) 87 ± 28.5 92 ± 28.6 83 ± 23.6 63 ± 13.5 107 ± 16.2 80 ± 8.3a 83 ± 19.0 93 ± 12.5
TBIL (mg/dL) 0.1 ± 0.04 0.2 ± 0.05 0.2 ± 0.04 0.2 ± 0.05 0.2 ± 0 0.2 ± 0.05 0.1 ± 0.05 0.1 ± 0b
N 5 4 5 4 5 5 5 4
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proclivity of mutations to occur in the kinase domains, 
inhibitors have striking variations in efficacy in clinical 
trials, particularly in lung cancers, which present with 
HER2 kinase mutations in 10% of lung adenocarcinomas 
and HER1 T790M mutations in more than 60% of cases 
[76, 77]. In comparison, studies with over 2000 breast 
cancer subjects and 1100 lung cancer subjects found 
mutations in the juxtamembrane domain of HER1 in 0% 
and 0.07% of cases, respectively [78–81]. When com-
pared to current TKIs, SAH5-EJ1 was significantly more 
effective, even in cancers with known tyrosine kinase 
domain mutations (Fig.  3b), emphasizing the benefits 
of targeting a domain in which activating mutations are 
clinically rare [82, 83]. Beyond the limitations currently 
described, the main therapeutic challenge associated 
with HER-driven cancers is the development of therapeu-
tic resistance, primarily driven by increased expression 
of HER family members. Yonesaka et  al. demonstrated 
Cetuximab (Erbitux; targets HER1) resistance is driven 
by HER2 upregulation and re-sensitizing resistant cells 
to Cetuximab requires inhibition of HER2/HER3 het-
erodimers—highlighting the importance of a pan-HER 
therapeutic such as SAH5-EJ1 [84]. We also observed 
therapeutic resistance in our models (Fig. 4e), but as we 
did not remove the primary tumors, we cannot speculate 
on the effects of SAH5-EJ1 on metastatic sites. This will 
be the subject of future experiments.
Glioblastoma multiforme (GBM) is associated with 
HER1 mutations in more than 40% of cases, particularly 
the EGFRvIII deletion mutation which alters the extracel-
lular domain to inhibit ligand binding while resulting in 
a constitutively active conformation, an event frequently 
associated with therapeutic resistance [56, 85]. Given the 
prominent role HER1 plays in promoting GBM, HER1-
directed inhibitors such as Gefitinib and Erlotinib are 
frequently administered but have proven unable to pen-
etrate the blood–brain-barrier, again highlighting the 
limitations of current HER-directed therapies [56, 86]. 
As our data demonstrated efficacy against orthotopically 
implanted EGFRvIII PDX models, it is likely that SAH5-
EJ1 can pass the blood–brain barrier, which is a subject 
of future studies.
Inflammatory breast cancer (IBC) is characterized by 
poor patient survival, high rates of metastasis, and lim-
ited targeted therapies [64, 67, 87]. Given the lack of 
understanding in identifying the drivers of IBC, current 
therapies have been wide-ranging and relatively ineffi-
cient. COX-2 (cyclooxygenase-2) has been demonstrated 
to be upregulated in IBC, known to moderate the produc-
tion of estrogen and interact with both HER1 and HER2, 
driving invasion and migration in the stem-cell-like pop-
ulation of cancer, making it a possible therapeutic target. 
However, given the ubiquity of COX-2 in healthy tissues 
as well as cancer, high toxicity levels of COX-2 inhibi-
tors have limited therapeutic use in clinical trials [65, 88]. 
Other therapies have tried to overcome upregulated Rho 
GTPase activity through a class of farnesyl transferase 
inhibitors, only to be limited by redundancies in Ras 
family member function and high toxicity levels [89, 90]. 
Nuclear transcription factor NFκB is highly upregulated 
in IBC, along with overexpression of HER1 and in some 
cases, HER2 and HER3, and we observed a decrease in 
the NFκB mediator IKKα when treated with SAH5-EJ1 
(Fig.  4g). IBC is also characterized by increased expres-
sion of mucin 1 (MUC1), which we have previously dem-
onstrated is responsible for altering the localization and 
trafficking of the HER receptors, limiting HER-driven 
therapeutic efficacy [12, 91, 92]. IBC can also present with 
upregulation of HER3, known for dimerizing with HER2 
and driving resistance to monoclonal antibody therapies, 
indicating the need for a therapeutic that targets multiple 
HER family members and can generate inactive dimers, 
such as SAH5-EJ1 [19, 93]. Future studies will investigate 
the lowest efficacious doses of SAH5-EJ1, but in this pre-
sent study we have illustrated the success of SAH5-EJ1 at 
0.5 µg/g body weight (Fig. 4d–f), well below the level of 
toxicity (Table S3, Additional file 1).
Conclusions
Through 2015, therapeutic peptides in clinical trials 
are dominated by those targeted at extracellular targets 
(more than 90%), with less than 7% designed for incs [94], 
indicating a clinical opportunity for a juxtamembrane-
directed pan-HER therapeutic. Our data indicate that 
SAH5-EJ1 is a highly efficacious HER-targeted therapeu-
tic, capable of reducing oncogenic activity in multiple 
cancers, both in  vitro and in  vivo. Additions of hydro-
carbon stapling have optimized the efficacy of the pep-
tide, including increased cell death and prolonged animal 
survival, allowing us to use lower concentrations within a 
therapeutic window ideal for the treatment of breast and 
lung cancers, including those with drug resistant-tumors.
Additional file
Additional file 1. Additional data for novel pan-HER therapeutic.  Figure 
S1. Cell line HER protein expression. Figure S2. IV-SAH5-EJ1 post 24 h. 
Figure S3. Glioma-luciferase in vivo. Table S1. Peptide COA. Table S2. 
Injection site reactogenicity. Table S3. Toxicity main study. Table S4. 
Treatment observation. Table S5. Absolute organ weight.
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